Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case -49% Improvement Relative Risk HCQ for COVID-19  Bhatt et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Prospective study of 927 patients in India More cases with HCQ (p=0.024) c19hcq.org Bhatt et al., medRxiv, August 2021 Favors HCQ Favors control

Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers

Bhatt et al., medRxiv, doi:10.1101/2021.08.02.21260750
Aug 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
Observational study of 927 low-risk healthcare workers in India, 731 volunteering for weekly HCQ prophylaxis, showing higher cases with treatment in unadjusted results. Clinical outcome was in the protocol, however no information on which patients were symptomatic is provided. There were no adverse events and no hospitalizations or deaths. Adherence was very low, decreasing weekly, with almost all participants discontinuing by week 11. The majority of infections occurred in later weeks when adherence was very low, and there was no per protocol analysis. #ECR/206/Inst/GJ/2013/RR-20.
risk of case, 49.3% higher, RR 1.49, p = 0.02, treatment 167 of 731 (22.8%), control 30 of 196 (15.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bhatt et al., 4 Aug 2021, prospective, India, preprint, 4 authors.
This PaperHCQAll
Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among Health-Care Workers
Parloop Bhatt, Vishva Patel, Prachi Shah, Keyur Parikh
doi:10.1101/2021.08.02.21260750
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus responsible for the ongoing Covid-19 pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine(HCQ) could prevent SARS CoV-2 in healthcare workers(HCW) at high-risk of exposure. Method: This voluntary observational study for the prevention and treatment of COVID-19 was conducted at a tertiary care center, from 12 th June to 12th October 2020(total 16 weeks). All consented asymptomatic HCW's of CIMS hospital were administered 400 mg HCQ twice a day on day one followed by 400 mg once weekly to be taken with meals up to 16 weeks. Data collected included OPD registration, risk assessment, medical and family history (related to COVID), physical examination and vitals, pulse oximetry, ECG (pre and post HCQ), drug adherence, side effects, adverse drug reactions. Result: The study enrolled 927 full-time, hospital-based HCWs ((including doctors, nurses, paramedical, lab technicians, sanitary workers and others), of whom 731(78.85%) initially started HCQ while 196 (21.14%) did not volunteer. The median age and weight of the study population was 27.5 years and 69.5 kg respectively. No major associated co-morbidities were present in these HCW's. There was an increased trend towards non adherence to HCQ with each proceeding week more so after week 11. Of the 731 HCW's taking HCQ a total of 167(22.8%) tested COVID positive at different intervals of time as against 30 HCW (15.3%) out of 196 not taking HCQ. The rate of COVID-19 positive was statistically significantly higher in the HCW's taking HCQ (p=0.0220; 95% CI: 1.14% to 12.94%), as compared to those not on HCQ. Thus HCQ was not prophylactically effective against COVID 19 infection. No
References
Abella, Jolkovsky, Biney, Uspal, Hyman et al., None
Agrawal, Akhil, Goel, Gupta, Emerging prophylaxis strategies against COVID-19: Pulmonary medicine and critical care jodhpur, Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2020.1289
Ben-Zvi, Kivity, Langevitz, Shoenfeld, Hydroxychloroquine: from malaria to autoimmunity, Clin Rev Allergy Immunol, doi:10.1007/s12016-010-8243-x
Bi, Wu, Mei, Ye, Zou et al., Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30287-5
Bienvenu, Marty, Jones, Picot, Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020, One Health, doi:10.1016/j.onehlt.2020.100141
Erkan, Yazici, Peterson, Sammaritano, Lockshin, A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome, Rheumatology, doi:10.1093/rheumatology/41.8.924
Fda / Cder, Plaquenil ® Hydroxychloroquine Sulfate Tablets, Usp Description
Fiehn, Ness, Weseloh, Specker, Hadjiski et al., Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review, Z Rheumatol, doi:10.1007/s00393-020-00785-4
Funk, Eggo, Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts, Lancet Glob Health, doi:10.1016/S2214-109X(20)30074-7
Gautret, Lagier, Parola, Van Thuan, Hoang et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Hellewell, Abbott, Gimma, Bosse, Jarvis et al., Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group
Kearney, Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel Coronavirus: Review, Preprints, doi:10.20944/preprints202003.0275.v1
Li, Guan, Wu, Wang, Zhou et al., Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N Engl J Med, doi:10.1056/NEJMoa2001316
Monti, Vertogen, Masini, Donati, Lilli et al., Hydroxychloroquine as Prophylaxis for COVID-19: A Review Front, Pharmacol, doi:10.3389/fphar.2020.605185
Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol, doi:10.1038/s41584-020-0372-x
Sharma Ajay, Natasha, Taraneh, Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review, J Am Acad Dermatol, doi:10.1016/j.jaad.2020.04.024
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
White, Cardiotoxicity of antimalarial drugs, Lancet Infect Dis, doi:10.1016/S1473-3099(07)70187-1
Yao, Ye, Zhang, Cui, Huang et al., In Vitro Antiviral Activity and Projection of Optimized Dosing
Zhaoa, Linc, Rand, Musae, Yangf et al., Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak, Int J Infect Dis, doi:10.1016/j.ijid.2020.01.050
Zhu, Zhang, Li, Yang, Song et al., China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019, N Engl J Med, doi:10.1056/NEJMoa2001017
{ 'DOI': '10.1101/2021.08.02.21260750', 'URL': 'http://dx.doi.org/10.1101/2021.08.02.21260750', 'abstract': '<jats:title>ABSTRACT</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Severe ' 'acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus responsible ' 'for the ongoing Covid-19 pandemic with no known effective prophylaxis. We investigated ' 'whether hydroxychloroquine(HCQ) could prevent SARS CoV-2 in healthcare workers(HCW) at ' 'high-risk of ' 'exposure.</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>This voluntary ' 'observational study for the prevention and treatment of COVID-19 was conducted at a tertiary ' 'care center, from 12<jats:sup>th</jats:sup> June to 12th October 2020(total 16 weeks). All ' 'consented asymptomatic HCW’s of CIMS hospital were administered 400 mg HCQ twice a day on day ' 'one followed by 400 mg once weekly to be taken with meals up to 16 weeks. Data collected ' 'included OPD registration, risk assessment, medical and family history (related to COVID), ' 'physical examination and vitals, pulse oximetry, ECG (pre and post HCQ), drug adherence, side ' 'effects, adverse drug ' 'reactions.</jats:p></jats:sec><jats:sec><jats:title>Result</jats:title><jats:p>The study ' 'enrolled 927 full-time, hospital-based HCWs ((including doctors, nurses, paramedical, lab ' 'technicians, sanitary workers and others), of whom 731(78.85%) initially started HCQ while ' '196 (21.14%) did not volunteer. The median age and weight of the study population was 27.5 ' 'years and 69.5 kg respectively. No major associated co-morbidities were present in these ' 'HCW’s. There was an increased trend towards non adherence to HCQ with each proceeding week ' 'more so after week 11. Of the 731 HCW’s taking HCQ a total of 167(22.8%) tested COVID ' 'positive at different intervals of time as against 30 HCW (15.3%) out of 196 not taking HCQ. ' 'The rate of COVID-19 positive was statistically significantly higher in the HCW’s taking HCQ ' '(p=0.0220; 95% CI: 1.14% to 12.94%), as compared to those not on HCQ. Thus HCQ was not ' 'prophylactically effective against COVID 19 infection. No participants in this study ' 'experienced grade 3 or 4 adverse events. No significant difference in the median of ECG ' 'changes in QTc between pre and post HCQ administration of 46 HCW’s was ' 'observed.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>This ' 'clinical study did not detect a reduction in SARS CoV-2 transmission with prophylactic ' 'administration of 400 mg/HCQ in HCW’s. All participants who did contract SARSCoV-2 were ' 'either asymptomatic or had mild disease courses with full recoveries. All adverse events were ' 'self-limiting and no serious cardiovascular events were reported with use of HCQ. In the ' 'absence of robust data, it seems premature to recommend HCQ as a prophylactic panacea for ' 'COVID-19.</jats:p></jats:sec>', 'accepted': {'date-parts': [[2021, 8, 4]]}, 'author': [ {'affiliation': [], 'family': 'Bhatt', 'given': 'Parloop', 'sequence': 'first'}, {'affiliation': [], 'family': 'Patel', 'given': 'Vishva', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Shah', 'given': 'Prachi', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Parikh', 'given': 'Keyur', 'sequence': 'additional'}], 'container-title': [], 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 8, 4]], 'date-time': '2021-08-04T17:20:40Z', 'timestamp': 1628097640000}, 'deposited': { 'date-parts': [[2021, 8, 6]], 'date-time': '2021-08-06T12:20:57Z', 'timestamp': 1628252457000}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'indexed': {'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T19:11:56Z', 'timestamp': 1648753916737}, 'institution': [{'name': 'medRxiv'}], 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2021, 8, 4]]}, 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.08.02.21260750', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '246', 'original-title': [], 'posted': {'date-parts': [[2021, 8, 4]]}, 'prefix': '10.1101', 'published': {'date-parts': [[2021, 8, 4]]}, 'publisher': 'Cold Spring Harbor Laboratory', 'reference': [ { 'DOI': '10.1056/NEJMoa2001316', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.1'}, { 'DOI': '10.1016/S1473-3099(20)30287-5', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.2'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.3', 'unstructured': 'World Health Organization. Report of the WHO-China Joint Mission on ' 'Coronavirus Disease 2019 (COVID-19). February 2020 ' '(https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf).'}, { 'DOI': '10.1016/j.ijid.2020.01.050', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.4'}, { 'DOI': '10.1056/NEJMoa2001017', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.5'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.6', 'unstructured': 'World Health Organization. Strengthening preparedness for COVID-19 in ' 'cities and urban settings. April 2020 ' '(https://www.who.int/publications-detail/strengthening-preparedness-for-covid-19-in-cities-and-urban-settings).'}, { 'DOI': '10.1016/S2214-109X(20)30074-7', 'article-title': 'Centre for the Mathematical Modelling of Infectious Diseases COVID-19 ' 'Working Group; Sebastian Funk, Rosalind M Eggo. Feasibility of ' 'controlling COVID-19 outbreaks by isolation of cases and contacts', 'doi-asserted-by': 'crossref', 'first-page': '488', 'journal-title': 'Lancet Glob Health', 'key': '2021080605200974000_2021.08.02.21260750v1.7', 'volume': '8', 'year': '2020'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.8', 'unstructured': 'Modes of Transmission of Virus Causing Covid-19: Implications for IPC ' 'Precaution Recommendations. Available from: ' 'https://www.who.int/newsroom/commentaries/detail/modes-of-transmission-of-virus-causing-Covid-19-implications-for-ipc-precaution-recommendations. ' '[Last accessed on 2020 Apr 23].'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.9', 'unstructured': 'Chemoprophylaxis of SARS CoV 2 Infection (Covid 19) in Exposed ' 'Healthcare Workers Full Text View ClinicalTrials. gov;2020. Available ' 'from: https://clinicaltrials.gov/ct2/show/NCT04328285. [Last accessed on ' '2020 Apr 23].'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.10', 'unstructured': 'The PATCH Trial (Prevention and Treatment of Covid 19 with ' 'Hydroxychloroquine) Full Text View ClinicalTrials.gov; 2020. Available ' 'from: https://clinicaltrials.gov/ct2/show/NCT04329923. [Last accessed on ' '2020 Apr 23].'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.11', 'unstructured': 'National Taskforce for COVID-19. Advisory on the use of ' 'hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection. 2020. ' 'https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf ' '(accessed March 23, 2020).'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.12', 'unstructured': 'National Taskforce for COVID-19. Revised advisory on the use of ' 'Hydroxychloroquine (HCQ) as prophylaxis for COVID-19 infection (in ' 'supersession of previous advisory dated 23rd March, ' '2020).https://www.mohfw.gov.in/pdf/RevisedadvisoryontheuseofhydroxychloroquineasprophylaxisforSARSCOVID19infection.pdf'}, { 'DOI': '10.1002/art.1780331001', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.13'}, { 'DOI': '10.1136/ard.2006.068676', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.14'}, { 'DOI': '10.1007/s40261-018-0656-y', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.15'}, { 'DOI': '10.1093/rheumatology/41.8.924', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.16'}, { 'DOI': '10.1038/s41584-020-0372-x', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.17'}, { 'DOI': '10.20944/preprints202003.0275.v1)', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.18'}, { 'article-title': 'Emerging prophylaxis strategies against COVID-19: Pulmonary medicine ' 'and critical care jodhpur', 'first-page': '1289', 'journal-title': 'Monaldi Archives for Chest Disease', 'key': '2021080605200974000_2021.08.02.21260750v1.19', 'volume': '90', 'year': '2020'}, { 'DOI': '10.1016/j.ijantimicag.2020.105949', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.20'}, { 'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged ' 'novel coronavirus (2019-nCoV) in vitro', 'first-page': '269', 'journal-title': 'Cell Res', 'key': '2021080605200974000_2021.08.02.21260750v1.21', 'volume': '3', 'year': '2020'}, { 'DOI': '10.1016/S1473-3099(07)70187-1', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.22'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.23', 'unstructured': 'FDA / CDER. Plaquenil ® Hydroxychloroquine Sulfate Tablets, Usp ' 'Description. FDA, 2017. http://www.cdc.gov/malaria'}, { 'DOI': '10.1093/cid/ciaa237', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.24'}, { 'DOI': '10.1016/j.antiviral.2015.01.011', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.25'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.26', 'unstructured': 'EMA (2020). COVID-19: reminder of the risk of chloroquine and ' 'hydroxychloroquine. Available at: ' 'https://www.ema.europa.eu/en/news/covid-19-reminder-risks-chloroquine-hydroxychloroquine ' '(Accessed May 29, 2020).'}, { 'DOI': '10.3389/fphar.2020.605185', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.27'}, { 'key': '2021080605200974000_2021.08.02.21260750v1.28', 'unstructured': 'Clinical trials register website (2020). Available at: ' 'https://www.clinicaltrialsregister.eu/ (Accessed June 15, 2020).'}, { 'DOI': '10.1016/j.onehlt.2020.100141', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.29'}, { 'DOI': '10.1007/s12016-010-8243-x', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.30'}, { 'DOI': '10.1007/s00393-020-00785-4', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.31'}, { 'DOI': '10.1016/j.jaad.2020.04.024', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.32'}, { 'DOI': '10.1001/jamainternmed.2020.6319', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.33'}, { 'DOI': '10.1093/cid/ciaa1571', 'doi-asserted-by': 'publisher', 'key': '2021080605200974000_2021.08.02.21260750v1.34'}], 'reference-count': 34, 'references-count': 34, 'relation': {}, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.08.02.21260750'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'subtype': 'preprint', 'title': 'Hydroxychloroquine Prophylaxis against Coronavirus Disease-19: Practice Outcomes among ' 'Health-Care Workers', 'type': 'posted-content'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit